nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

21.03.2019 | Short Communication

Rituximab dosing in hematological malignancies: an old question, revisited

verfasst von: Peter N. Morcos, Axel Boehnke, Nancy Valente, Donald E. Mager

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Rituximab is the standard of care for most B-cell malignancies. Its rapid clinical development enabled patients to receive this life-prolonging medicine sooner; however, it precluded a thorough assessment of dose selection. Extensive clinical pharmacology data collected from the recent subcutaneous development program enabled re-examination of this old question and support that the approved rituximab dosing regimens in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia appear to maximize the clinical benefit in the majority of patients.

Salles G, Barrett M, Foa R et al (2017) Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 34(10):2232–2273. https://doi.org/10.1007/s12325-017-0612-x. Epub 2017 Oct 5CrossRefPubMedPubMedCentral

Davies A, Berge C, Boehnke A et al (2017) Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther 34(10):2210–2231CrossRefPubMedPubMedCentral

Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) Meeting on March 29 (2017) https://www.fda.gov/AdvisoryCommittees/Calendar/ucm547160.htm. Accessed 2 Jan 2019

Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) Meeting on March 29 (2017) Roche Briefing package. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm547155.htm. Accessed 20 Mar 2019

Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) Meeting on March 29 (2017) FDA Briefing package. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm547155.htm. Accessed 20 Mar 2019

Li J, Zhi J, Wenger M et al (2012) Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol 52:1918–1926CrossRefPubMed

Gibiansky E, Gibiansky L, Carlile DJ et al (2014) Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma and exposure-response in CLL. CPT Pharmacomet Syst Pharmacol 29;3:e144. https://doi.org/10.1038/psp.2014.42 CrossRef

Berinstein NL, Grillo-López AJ, White CA et al (1998) Association of serum rituximab (IDECC2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 9(9):995–1001CrossRefPubMed

Gibiansky E, Brewster M, Chavanne C et al (2015) Comparison of population PK and exposure-response relationships of intravenous rituximab and subcutaneous rituximab in patients with CLL. Poster session presented at: 2015 PAGE annual meeting, June 2–5, Hersonissos, Crete, Greece

10.

Dayde D, Ternant D, Ohresser M et al (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113(16):3765–3772. https://doi.org/10.1182/blood-2008-08-175125 (Epub 2008 Nov 24) CrossRefPubMed

11.

Yin A, Li J, Hurst D et al (2010) Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non-Hodgkin’s lymphoma. J Clin Oncol 28(suppl 15):e13108CrossRef

12.

Maloney DG, Grillo-López AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195PubMed

13.

Lazzarino M, Arcaini L, Orlandi E et al (2005) Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma. Oncology 68:146–153CrossRefPubMed

14.

Gordan LN, Grow WB, Pusateri A et al (2005) Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23:1096–1102CrossRefPubMed

15.

Igarashi T, Kobayashi Y, Ogura M et al (2002) Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 13:928–943CrossRefPubMed

16.

Tobinai K, Igarashi T, Itoh K et al (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821–830CrossRefPubMed

17.

Jäger U, Fridrick M, Zeitlinger M et al (2012) Rituximab serum concentrations during immunochemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 97:1431–1438CrossRefPubMedPubMedCentral

18.

Kamisoglu K, Phipps A, Jamois C et al (2017) Greater efficacy and potency of obinutuzumab compared with rituximab in chronic lymphocytic leukemia patients confirmed by a semi-mechanistic pharmacokinetic/pharmacodynamic model. Blood 130(Suppl 1):1267. http://www.bloodjournal.org/content/130/Suppl_1/1267. Accessed 2 Jan 2019

Titel: Rituximab dosing in hematological malignancies: an old question, revisited
verfasst von: Peter N. Morcos
Axel Boehnke
Nancy Valente
Donald E. Mager
Publikationsdatum: 21.03.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2019
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03818-1

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Rituximab dosing in hematological malignancies: an old question, revisited

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review

A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer

The role of thioredoxin system in cancer: strategy for cancer therapy

Genistein combined with FOLFOX or FOLFOX–Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study

Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response

Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie